MDT-AP-1273
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- overall_survival_months
- 156
- os_event
- false
- age_years
- 11
- sex
- M
- new_clusters
- S3
- umap1_2d
- -3.225100543
- umap2_2d
- -7.602488646
- umap1_3d
- -2.943828905
- umap2_3d
- -3.213560411
- umap3_3d
- 7.998417731
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYOGENESIS+0.380
- INTERFERON_ALPHA_RESPONSE+0.310
- KRAS_SIGNALING_DN+0.230
- IL6_JAK_STAT3_SIGNALING+0.190
- COAGULATION+0.180
- INTERFERON_GAMMA_RESPONSE+0.160
- UV_RESPONSE_DN+0.160
- BILE_ACID_METABOLISM+0.150
- COMPLEMENT+0.150
- APICAL_SURFACE+0.140
Top 10 suppressed
- E2F_TARGETS-0.680
- G2M_CHECKPOINT-0.620
- MYC_TARGETS_V1-0.620
- DNA_REPAIR-0.460
- MTORC1_SIGNALING-0.340
- MITOTIC_SPINDLE-0.320
- MYC_TARGETS_V2-0.320
- PROTEIN_SECRETION-0.310
- UNFOLDED_PROTEIN_RESPONSE-0.290
- OXIDATIVE_PHOSPHORYLATION-0.270
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MDT-AP-0759 | Med | Medulloblastoma | 0.904 |
| 2 | TCGA-55-8513-01A-11R-2403-07 | — | cohortA1 | 0.886 |
| 3 | s0112320 | — | — | 0.880 |
| 4 | BS_R244Z0WX | pilocytic astrocytoma | — | 0.860 |
| 5 | BS_XKKB4MZV | pilocytic astrocytoma | — | 0.860 |
| 6 | SRR1797234 | — | cohortMD2 | 0.857 |
| 7 | TCGA-55-8619-01A-11R-2403-07 | — | cohortA1 | 0.851 |
| 8 | TCGA-A7-A13H-01A-11R-A22K-07 | — | A | 0.850 |
| 9 | TCGA-55-8621-01A-11R-2403-07 | — | cohortA1 | 0.849 |
| 10 | BS_NPQJ20KX | pilocytic astrocytoma | — | 0.848 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 25 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYOGENESIS | 0.380 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.310 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.230 | Remibrutinib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.190 | Inavolisib | — uncovered |
| COAGULATION | 0.180 | Binimetinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.160 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.160 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.150 | Inavolisib | — uncovered |
| COMPLEMENT | 0.150 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.140 | Temsirolimus | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.140 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.120 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.100 | Inavolisib | — uncovered |
| HYPOXIA | 0.090 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.090 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.080 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.080 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.060 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.060 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.030 | Remibrutinib | — uncovered |